Phase Space AI

Valuation and Trade

Twist Bioscience [TWST]

Twist Bioscience [TWST] — Valuation, Criteria Scorecard, Trade Construction & Catalysts

Phase Space Research | original 2026-07-27 · methodology update 2026-07-29 | framework v1.7.0 (Criteria ruleset, references/criteria.md 2026-07-29) | Price at update $88.62 (2026-07-28 close) | EV $5.35bn (Fiscal year ends 30 September.)

This memo no longer issues a position verdict. It scores Criteria and produces two valuation outputs. Sections written under the retired "Gate / E[R] vs cash hurdle" ruleset are marked SUPERSEDED where their conclusions no longer stand. Their evidence is retained deliberately — and in TWST's case the earnings-quality evidence in §0.7 is untouched by the valuation fix and is the most important thing in this document.

---

0. Methodology update — 2026-07-29. What changed, and why the answer moved

0.1 The old conclusion, and the defect that produced it

The 2026-07-27 memo concluded "WATCHLIST — no position; probability-weighted value $38.64 against an $86.54 spot; scenario-weighted E[R] −55.4% (range −48.7% to −65.3%) against a +4.7% cash hurdle, a −60.1pp shortfall." Two defects produced that number:

1. The exit multiple came from a comparator set with no growth dispersion — base 5.5x sales against a diagnostics/tools peer set spanning 1.0–7.5% revenue growth (ILMN 1%, QGEN 3%, BRKR 2%, DGX 7.5%, LH 7.0%) applied to a 23% grower. The slope was unidentified and then extrapolated well beyond its support.
2. The sensitivity ran over scenario probabilities. §3.2 solved for a bear weight of −241% and correctly concluded that no probability assignment could change the answer — which is the proof that the analysis was run on the wrong parameter. Sensitivity now runs over the exit multiple.

0.2 Inputs — pre-computed, with one correction

From the pre-computed scan at reports/scan/TWST_analysis.json (as-of 2026-07-28) rather than recomputed here.

Resulting EV: $5,345m = 13.05x TTM revenue.

0.3 The implied-path test (reverse DCF) — the Valuation Criteria

assets/reverse_dcf.py, solving for revenue CAGR. Held fixed: terminal EBIT margin 20.0%, exit multiple 33.1x EBIT, WACC 10.0%, horizon 5 years, EV $5,345m, revenue base $409.5m.

What the price requires: a 26.0% five-year revenue CAGR.

What Twist has demonstrated: 22.8%.

MARGIN = demonstrated − required = −3.2 percentage points. Valuation Criteria: FAIL — but narrowly.

The exit multiple and its compression, as a number. 33.1x EBIT at a 20% terminal margin is 6.62x exit-year sales, against 13.05x trading today — a −49.3% implied compression. Basis GROWTH_MATCHED with n=23, the widest qualifying set in this batch (comparators from 11.4% to 27.1% growth, bracketing Twist's 22.8% on both sides). This anchor is the least contestable of the four, which makes the −3.2pp result the most trustworthy of the four even though it is the narrowest.

Can the gap be closed by argument? Per the Criteria, a PASS WITH ARGUMENT requires a specific, evidenced reason the business will exceed what it has demonstrated — a named product cycle, mix shift or pricing action. Twist has candidates: 13 consecutive sequential-growth quarters, gross margin 42.6% → 50.7%, the AWS/Amazon Bio Discovery wet-lab partnership. They are not accepted here, for a reason specific to this name and set out in §0.7: the company retired its orders disclosure — a forward demand indicator — to exactly zero for six consecutive quarters, in the same quarter series in which it began promoting an adjusted-EBITDA metric that excludes $64.5m of stock-based compensation, 17.1% of FY2025 revenue. An acceleration argument requires forward-looking evidence, and the company withdrew the forward-looking disclosure. Narrative does not qualify.

0.4 Sensitivity — over the exit multiple, never over scenario probabilities

Break-even exit multiple: 37.6x EBIT / 7.53x exit sales at the demonstrated 22.8% CAGR — 14% above the growth-matched anchor. TWST is the one name of the four whose verdict sits inside the plausible band of the anchor itself. This is a FAIL by 3.2pp, not a FAIL by 60pp, and the difference from the old memo's −60.1pp framing is the entire point of the correction. It should not be reported as though the two are the same finding.

Second sensitivity. Holding 22.8% growth and 33.1x, the break-even terminal EBIT margin is 22.7% — above the 20% assumed. Twist's FY2025 GAAP operating margin was −36.2% (improving +34.4pp YoY, which is real). The price requires a business that has never earned a positive operating margin to terminate above the flat 20% the scan assumes for everyone.

0.5 Caveat on the terminal margin

The scan does not persist terminal_margin; back-solving from its published required_cagr_pct returns exactly 0.2000 for NTRA, GH and TWST alike — a flat 20% for every name. It is an assumption, not a measurement, and §0.4's break-even (22.7%) shows TWST is the name where it binds hardest.

0.6 The 12-month target

• Revenue base: TTM $409.5m grown at the Street's implied FY2026 growth (+18.1%: consensus FY2026E $444.69m, 10 analysts, cached 2026-07-27, vs FY2025 actual $376.6m) → NTM $484m. Disclosed gap: FY2027E consensus is not on file and the Alpha Vantage quota (25/day, shared) was exhausted on 2026-07-29. Per the Consensus Criteria a quota gap leaves the field blank and blocks nothing.
• Multiple anchor — Twist's own EV/Sales history, 2022-07-01 to 2026-07-28 (1,021 trading days, EV rebuilt daily from then-current shares and then-reported TTM revenue): today 12.92x = the 96th percentile of the four-year range (min 2.20x, median 6.68x, upper quartile 8.34x, max 16.34x); 92nd percentile of the trailing twelve months alone (1y median 6.24x).

Base is the four-year upper quartile, not either median, because Twist has genuinely re-rated on an evidenced margin inflection (gross margin 42.6% → 50.7%, operating margin +34.4pp) and reverting to a median set during the pre-inflection period would be reverting to a different business. But the anchor choice dominates the answer here more than for any other name in the batch — the band is −42% to +16% — and that is stated rather than hidden inside a point estimate.

Named 12-month product-cycle events feeding it (dated in §4): FQ3-2026 earnings 3 August 2026; the FQ4-2026 adjusted-EBITDA breakeven test (~November 2026); FY2027 guidance. All dated in the original memo.

Sanity band. Street average target $92.50 (+6.9%), median $98.50, range $36–$120. The external healthcare specialist's book (snapshot 2026-07-28) carries TWST long at a −4% expected return on a thesis of "outsourced antibody validation is the most obvious AI use case in biology" — i.e. he owns it while expecting a negative return, sized small, because his selection statistic is return per unit of implied volatility and his book gets optionality and factor fit from the position. That is a different question from the one this memo answers, and it is the clearest illustration in the batch of why the memo no longer issues a position verdict.

0.7 Earnings quality — UNAFFECTED by the valuation correction, and preserved in full

The anchoring defect had nothing to do with these findings and fixing it does not soften them.

1. orders was de-disclosed to exactly zero for six consecutive quarters (mention frequency 24.1 → 21.4 → 10.5 → 22.5 → 14.3 → 6.8 → 13.7 → 0.0 × 6). Orders is a forward-looking demand indicator. The company disclosed it and stopped.
2. In the same quarter series, management began guiding to an adjusted-EBITDA metric that adds back $64.5m of stock-based compensation — 17.1% of FY2025 revenue — while that SBC funds roughly 2.5%/yr of real shareholder dilution. The guided metric excludes the largest real cost.
3. The two moved together. A forward indicator was withdrawn as a flattering non-GAAP metric was promoted.

This is why §0.3 declines to grant PASS WITH ARGUMENT, and it is the single most important thing in this document. It is scored under Quality Criteria (accruals/earnings-quality limb, retained on both archetypes), not under valuation.

0.8 Criteria scorecard (Gates retired 2026-07-29)

Archetype: INFLECTION.

0.9 What moved, in one line

Old: worth $38.64 against an $86.54 spot; E[R] −55.4%; a −60.1pp shortfall; WATCHLIST. New: the price requires a 26.0% revenue CAGR against 22.8% demonstrated — a −3.2pp margin, FAIL, narrowly — with a 12-month base target of $67.55 (−23.8%) inside a −42% to +16% band. Why it moved: the exit multiple now comes from 23 comparators that bracket Twist's growth on both sides (33.1x EBIT ≈ 6.6x sales) rather than 5.5x sales pulled from 1–7.5% growers, and the question changed from asserting a path to solving for what the price requires. The finding is not "TWST is cheap" — it still fails. The finding is that it fails by 3 points, not 60, and the verdict is decided by an exit multiple sitting 14% away. The earnings-quality findings in §0.7 are unchanged and are the reason the gap is not argued away.

---

0. Model provenance — the inherited model was NOT sound, and the catch matters

The brief instructed me to inspect and reuse the partial model left by the spend-limit-terminated run rather than rebuild it, on the basis that it had been "reported as verified: balance check zero, FY2026E inside guidance."

Both of those claims were true. The model was still materially wrong.

The FY2025 cost base was understated by roughly $96m, and because every forecast year was driven off those percentages, the error propagated through the entire ten-year forecast, the unlevered FCF, and the DCF.

The lesson, and it belongs in the framework: a zero balance check verifies internal CONSISTENCY, not input ACCURACY. The prior model balanced perfectly to the penny in all twelve columns both before and after the correction, because the balance check is a closed loop over the model's own numbers. Verification must include a tie-out of actual-year lines to the filed statements. It is logged in §7.

The model was rebuilt from scratch with the filed cost base. It now ties out:

---

1. Valuation

1.1 DCF — reported, and then explicitly discarded as the wrong tool

This DCF is unusable and is shown in order to prove it, not to be relied on. With stock-based compensation treated as the real cost it is, TWST's unlevered free cash flow is negative in nine of the ten forecast years and does not turn positive until FY2032E. A ten-year DCF over such a profile returns a negative enterprise value — an artifact of the window and the discount rate, not a valuation.

This is exactly the GH precedent (terminal value 98.8% of EV → down-weight) and the SMR precedent (pre-profit → use scenario and liquidity analysis instead), and it is handled the same way: the scenario framework in §1.2 and the liquidity-runway analysis in §1.5 carry the valuation weight. The sensitivity grid below is reported for completeness only.

1.2 Scenario framework — this carries the weight

Valued on FY2030E revenue at an anchored exit multiple, discounted back 4 years at 16.44%.

SUPERSEDED (2026-07-29). Probability-weighted value $38.64 · Scenario-weighted expected return −55.4% · versus a 4.7% cash hurdle, a shortfall of −60.1 percentage points. This output is retired. The cash hurdle no longer exists in the framework, and the exit multiples below (3.0x / 5.5x / 8.5x) were anchored on a 1.0–7.5% growth peer set applied to a 23% grower. The revenue and margin build is kept; its valuation conclusion is not. Replacement: §0.3. The corrected result is a FAIL by 3.2pp, not by 60.1pp.

And here TWST is more stretched than TXG. At a benign 10% discount rate, the Bull case is worth $85.19 and the stock trades at $86.54. The market is paying slightly MORE than the bull case discounted at a sector-typical rate. On TXG the equivalent figure was $46.64 against a $45.92 price — the bull case was exactly paid for. On TWST it has been exceeded.

Where the exit multiples come from — anchored, not picked. Bear 3.0x ≈ Bruker (3.4x, 2% growth, 50% GM — the closest analogue for a low-margin manufacturer). Base 5.5x sits between Qiagen (4.7x) and Illumina (6.8x). Bull 8.5x is a full re-rating above today's 7.5x peer median, granted for flawless execution.

Robustness. Holding base FY2030E revenue at $780m: $36.42 at 5.5x · $44.9 at 7.0x · $48.2 at 7.5x (today's peer median) · $54.0 at 8.5x. Even at today's peer median applied four years forward, the stock is 44% overvalued. The conclusion does not depend on the multiple choice.

1.3 Comparables

TWST trades at 12.7x LTM sales (11.7x the FY2026 guide) on the lowest gross margin in the set. That mismatch — highest-but-one multiple, lowest margin, flat underlying category, still cash-burning — is the core of the valuation case. The genuine offset, stated plainly: TWST also has the second-highest growth rate in the set and the only rising margin.

1.4 Consensus bridge (required)

Decomposing the disagreement — numbers or multiple? Entirely the multiple. House and Street are 0.4% apart on FY2026E revenue, and both are inside company guidance. There is no near-term estimate variant. The entire $54 gap comes from the exit multiple applied to an agreed revenue path: the Street is implicitly capitalising FY2030E revenue at roughly 12x; the house uses 5.5x, anchored on Qiagen and Illumina.

And as with TXG, the direction of travel in consensus is the striking part:

Three targets raised 33–55% inside eleven days. The resulting average target of $92.50 is only 6.9% above the current price — i.e. after those raises, the Street's average implies a 12-month return barely above the risk-free rate. The lowest target on the Street is $36, which sits almost exactly on the house's bear case of $17–$36 range. The dispersion ($36 to $120, a 3.3x spread) is itself the honest signal: nobody knows.

1.5 Liquidity-runway analysis — for a pre-profit name, this is the real valuation work

Additional calls on liquidity: a securities class-action settlement in principle of ~$17.1m, and capex running at 7.4% of revenue (~$33m/yr). Additional sources: a $15.0m sale-of-future-revenue liability (originated 21-Oct-2024, a royalty monetisation) and an automatic shelf registration (S-3ASR) filed 18 June 2026 — six weeks before the 3 August print.

The model's own runway rows: 2.9 years at the FY2026E burn, 7.6 years at FY2027E, self-funding from FY2028E. That is on the base case delivering. If FQ4-2026 breakeven slips, the equity raise becomes live inside twelve months — into a float that is 25.5% short.

---

2. Factor & Anomaly Scorecard

Synthesis. Momentum, trend, revisions and the guidance record all support ownership. The negatives are the multiple, the burn, and the crowding. TWST scores better on the anomaly factors than TXG does — its revisions are positive where TXG's are negative — and that difference is real and is reflected in the slightly higher probability weight given to its bull case.

2.1 The batch premise was wrong — the same correction as TXG

The brief stated that TXG and TWST "arrive cheap and beaten-up rather than extended," and would test calibration item B1 (does Gate 6 penalise buying weakness?).

Momentum is entry timing, not selection (2026-07-29). Every clause in this subsection that treats a momentum decile as a reason to own, not own, or veto a name is retired. Momentum Criteria is MEASURED and blocks nothing. Current readings: 12-1 +169.2% (83.7th percentile), 6-1 +131.0% (92.9th), RSI-14 49.0. Original text follows.

TWST is a top-decile momentum name trading 68% above its 200-day moving average. Gate 6 is a tailwind on the long side. It does not bind, and calibration item B1 is not tested by this name either. See §7.

---

3. Trade Construction — the four conclusions, kept separate

1. Fundamental conclusion — POSITIVE, and more clearly so than TXG. Thirteen consecutive quarters of sequential revenue growth; +19% y/y in FQ2-2026; gross margin +14 points in three years and still rising; guidance raised twice this fiscal year; genes shipped +32%; a dated, twice-reiterated path to adjusted-EBITDA breakeven; AWS naming Twist a wet-lab partner for Amazon Bio Discovery. This is a business executing.
2. Expectations conclusion — FULLY DISCOUNTED. 11 analysts at Buy; consensus revenue within 0.4% of the house build; the stock +140% in twelve months; three targets raised 33–55% in eleven days, after which the average target sits just 6.9% above spot. There is no expectations gap in the house's favour.
3. Valuation conclusion — RESTATED 2026-07-29. (Was: "NEGATIVE — probability-weighted value $38.64 vs $86.54.") On the implied-path test the price requires a 26.0% five-year revenue CAGR against 22.8% demonstrated: a −3.2pp margin, Valuation Criteria FAIL — narrowly, flipping to PASS at an exit multiple only 14% above the growth-matched anchor. 12-month base target $67.55 (−23.8%). See §0.3–§0.6.
4. Portfolio conclusion — REMOVED. (Was: "NO POSITION.") This memo issues no position verdict. It scores Criteria (§0.8) and produces two valuation outputs. The short-side observations (25.5% of float short at 6.9 days to cover) are retained as Short Mechanism Criteria and Liquidity Criteria evidence, not as a recommendation.

3.1 Criteria-by-Criteria (evidence retained; verdicts restated in §0.8)

"Gates" were retired on 2026-07-29. Below is the original gate block with names mapped forward. The reasoning column is unaltered — it is the record. Where a verdict changed, §0.8 is authoritative.

THE BINDING GATE IS GATE 4 (expected return), with Gate 2 failing independently on both branches.

Gate 6 does not bind on the long side — it is a tailwind. Gate 5 does not bind on the long side either. If Gate 6 were deleted from the framework, the decision on TWST would be unchanged.

For a SHORT — which is not the recommendation — the binding gates would be 5 and 6 jointly, which is exactly the pattern calibration item S1 describes.

3.2 E[R] range and flip point (SUPERSEDED 2026-07-29 — this is the defect, preserved)

Read this as the exhibit, not the analysis. It ranges over scenario probabilities, solves for a bear weight of −241% — outside [0,1] — and concludes that no probability assignment can change the answer. That is the proof the sensitivity was run on a parameter that could not move the result. The replacement, a sensitivity over the exit multiple with a break-even multiple stated, is §0.4. The conclusions below, including the $36.90 "entry", do not stand.

E[R] RANGE: −48.7% to −65.3%. Cash hurdle: +4.7%.

The hurdle sits FAR OUTSIDE the range. Even at a 0% bear weight — assuming the bear case cannot happen — expected return is −48.7%, still 53 percentage points below the hurdle.

FLIP POINT on bear weight: UNREACHABLE. No weighting of these three scenarios produces a passing expected return; solving returns a bear weight of −241%, outside [0,1]. The decision does not turn on the scenario probabilities — calibration item B7's criticism of Gate 4 does not apply here.

FLIP POINT on price: $36.90. At $36.90 (−57.4% from spot) the probability-weighted expected return equals the 4.7% cash hurdle. That is the entry level and the actionable output. (Note: the Street's own lowest target is $36 — the house entry and the most bearish analyst on the tape agree almost exactly.)

3.3 Liquidity Criteria (was Gate 5) — implementation feasibility, assessed early

Liquidity Criteria verdict (restated 2026-07-29): PASS on equity; FAIL on options — peak open interest 501 contracts at a single strike, most under 50, many at zero, and a 44%-of-mid quoted spread. Per the Criteria, a vehicle that cannot be filled is not a vehicle. (The original line read "PASS for a long in equity; FAIL for a short"; borrow and short interest are no longer part of this Criteria on a long-only book — they are scored under Short Mechanism Criteria.) Original text follows.

Gate 5 verdict: PASS for a long in equity; FAIL for a short; options too wide and too rich for any structure. The short-side failure here is a direct instance of calibration item S2 (Gate 5 as the terminal state for shorts) — though in this case the short also fails Gates 1 and 6 on the merits, so Gate 5 is not doing the work alone.

3.4 Analysis summary — no position verdict is issued

POSITION VERDICT: NONE. This memo does not output Long / Short / Watchlist / Avoid.
                  It outputs an analysis. Whether it justifies a position belongs to a book.
                  The external reference manager is LONG TWST at a -4% expected return; an
                  absolute-return book would not be. Same analysis, two answers.

VALUATION CRITERIA (implied path, 5y):  price requires 26.0% revenue CAGR
                                        demonstrated 22.8%   MARGIN -3.2pp   FAIL - NARROWLY
   exit multiple 33.1x EBIT = 6.62x exit sales, basis GROWTH_MATCHED (n=23, the best-identified
   anchor in this batch; comparators span 11.4%-27.1% growth, bracketing TWST on both sides)
   implied compression from 13.05x trading today: -49.3%
   FLIPS TO PASS above a 37.6x EBIT exit multiple - only 14% above the anchor
   Break-even terminal EBIT margin 22.7%, ABOVE the 20% assumed
12-MONTH TARGET: $67.55 base (-23.8% to $88.62 spot); low $51.25 (-42.2%); high $103.12 (+16.4%)
                 multiple anchored on TWST's OWN EV/Sales history (12.92x = 96th pctile of 4y,
                 92nd pctile of 1y); revenue base NTM $484m off Street FY2026E
QUALITY CRITERIA (BINDING): PASS on all three INFLECTION limbs - gross margin 50.7%,
                 operating margin +34.4pp YoY (largest in the batch), growth 22.8%.
                 EARNINGS-QUALITY LIMB FLAGGED: `orders` de-disclosed to zero for six straight
                 quarters while an adjusted-EBITDA metric excluding $64.5m of SBC (17.1% of
                 FY2025 revenue) was promoted. UNAFFECTED by the valuation correction. See §0.7.
LIQUIDITY CRITERIA (BINDING): PASS on equity ($5.5bn cap, ~$135m ADV);
                 FAIL on options - peak OI 501 at one strike, most under 50, 44%-of-mid spreads
MOMENTUM CRITERIA (MEASURED - ENTRY TIMING ONLY, NEVER SELECTION):
                 12-1 +169.2% (83.7th pctile), 6-1 +131.0% (92.9th), RSI-14 49.0
DOWNSIDE CRITERIA (MEASURED): FQ4-2026 breakeven met only on the SBC-excluding definition while
                 the GAAP loss persists, forcing a raise off the 18-Jun-2026 shelf into a de-rating
CATALYST / PEER SPREAD / CONSENSUS / SHORT MECHANISM: see §0.8
TIME HORIZON:    FQ3-2026 earnings (3 Aug 2026), then the FQ4-2026 breakeven test (~Nov 2026)
CONSENSUS:       Street Buy, 11 analysts, average target $92.50 (+6.9%), range $36-$120.
WHAT WOULD CHANGE THE VALUATION CRITERIA VERDICT (not a position trigger):
- FQ4-2026 adjusted EBITDA positive AND GAAP operating loss below $25m in the quarter
- FY2027 revenue guidance above $530m
- Gross margin sustained above 54% for two consecutive quarters
- REINSTATEMENT of the `orders` disclosure - the single cleanest refutation of §0.7
- An equity raise off the 18-Jun-2026 shelf at any price (evidence for the downside case)
INVALIDATION TRIGGERS:
- FQ4-2026 (Sep-2026 quarter) adjusted EBITDA positive AND GAAP operating loss below $25m
- FY2027 revenue guidance above $530m (vs the house base of $517m)
- Gross margin sustained above 54% for two consecutive quarters
- An equity raise off the 18-Jun-2026 shelf at any price (bearish confirmation)
- Realised price per gene stabilising (revenue growth converging on unit growth)

This is the "good business, contested price" case. Unlike TXG — where the fundamental trajectory is itself negative — TWST's operating story is genuinely positive and the memo says so without hedging. (Restated 2026-07-29: the original sentence continued "…and the market has already paid more than the bull case", which rested on the retired scenario framework. On the corrected method the Valuation Criteria fails by 3.2 percentage points and would pass at an exit multiple 14% higher. The refusal is not emphatic; it is narrow, and the earnings-quality findings in §0.7 — not the valuation — are why the gap is not argued away.)

3.5 Vehicles priced, and why each was rejected

Alpaca options data pulled live, 2026-07-27.

Variance risk premium check (mandatory before any naked premium). ATM implied volatility runs 78–98% across the four expirations against 68.2% realised — implied is 1.2–1.4x realised across the surface. On the put side, 85-strike August IV of 80.3% against 68.2% realised means downside is not cheap. There is no expiration where a house expected move exceeds the option-implied move, because the house has no directional variant to express. Per references/alpaca-options.md, the correct answer to "which vehicle" is: none.

IV crush would hit any structure hard: TWST reports 3 August 2026, seven days out, and August IV will collapse immediately afterward regardless of direction.

3.6 Portfolio-book context (portfolio_book.json contract executed)

Book is 100% cash; config: 5% single-name max, 4.7% cash hurdle, −2%-of-book position hard stop, 25% sector concentration cap, 0.60 pairwise-correlation disclosure threshold.

• Capital competition — SUPERSEDED. (Was: "FAILS decisively. Net E[R] −55.4% vs a risk-free 4.7%.") The cash hurdle has been retired from the framework; capital competition is slot competition inside the strategy and the memo does not run it. On the Criteria the memo does score, the Valuation Criteria fails by 3.2pp. Original text follows.
• (superseded) Net E[R] −55.4% vs a risk-free 4.7%. Cash wins by 60 percentage points.
• Correlation: TWST's mean correlation to the ten-name AI-infrastructure cluster is +0.199 (per the GH memo's cross-check, same date) — genuinely diversifying. And, as the ISRG and GH memos both concluded, that is a reason to prioritise a name for conversion, never a reason to own something with a negative standalone expected return. Diversification scales a positive edge; it cannot manufacture one.
• Sector concentration: TWST and TXG would together form one life-science-tools cluster against the 25% cap. Neither converts today, so no constraint binds.
• Write-back: Watchlist entry with two-sided conversion triggers, in PENDING_book_and_ledger_updates.json.

3.7 Joint probability the conversion triggers fire together (v1.4.2, item C6)

→ LONG conversion. Two paths, OR'd:

P(either fires) ≈ 28–33%. P(both fire together) ≈ 2%.

The relevant number under item C6 is P(the long conversion becomes live) ≈ 28–33% over twelve months — comfortably above the ~10% threshold. This Watchlist is REAL, not a no-position wearing a watchlist costume.

Note the honest caveat on T2, which is the more interesting path: even if all three of its conditions fire, they move the base case toward the Bull column ($68.36) — which is still 21% BELOW today's price. So T2 alone does not actually create a long at $86.54; it creates one only in combination with a lower price. That is a material qualification and it is stated rather than buried.

→ SHORT conversion. Three conditions, all required (AND'd):

JOINT probability all three fire together: ~1.6%. Allowing generously for positive correlation, ~4%.

That is below the ~10% threshold. The SHORT conversion on TWST is honestly classified as NO POSITION wearing a watchlist costume — and it is compounded by Gate 5 failing outright at 25.5% of float short. It is recorded as such rather than left on the book as a live trigger.

---

4. Catalyst Calendar

---

5. What would make me wrong

1. The execution record is the best in this coverage. Thirteen straight sequential-growth quarters through the worst tools downturn in twenty years, with guidance raised twice this year. Betting against that record has been wrong repeatedly.
2. Penetration is ~9.4%. Unlike TXG (~96% of its serviceable market on the same method), TWST genuinely has room. If the customer-acquisition rate inflects, the Bull column is conservative.
3. The AI-protein-design demand wave is real, corroborated, and I cannot size it. PubMed inflecting 107 → 172 → 153 YTD, plus AWS naming Twist a wet-lab partner. If synthetic DNA becomes the physical bottleneck for AI-designed biology, TWST's growth rate is the wrong anchor entirely.
4. The Atlas stake is given zero value and is not zero.
5. 25.5% of float short. A clean FQ4 breakeven print could squeeze this violently, and being right about valuation would not help.
6. The exit multiple is doing all the work. At ~12x FY2030E EV/Sales — where the market is — the stock is fairly valued. My 5.5x rests on Qiagen and Illumina, which are anchors, not laws.

---

6. Feedback for the screener (idea-screener)

TWST, like TXG and GH, was believed to be a non-momentum-selected value name. It is a top-decile momentum name 68% above its 200-day. Three consecutive memos have now found the same thing. The stage_c_cap: 75 truncation identified in the GH memo — which pushed the effective momentum threshold to +405% against a stated +160% — remains the binding constraint on what reaches underwriting, and it is producing systematically wrong priors about which names are cheap.

---

7. Calibration Watch entries generated by this memo

These are logged, not acted on. No gate has been loosened.

---

Prepared by Phase Space Research, 2026-07-27. Options quotes, Greeks and IV: Alpaca (live, 2026-07-27). Price, volatility and beta: Alpaca SIP daily bars. Consensus, targets, short interest and float: public aggregators (stockanalysis.com), 2026-07-27. Fundamentals: SEC EDGAR. Model: TWST_Financial_Model.xlsx, rebuilt from the filed cost base and verified by reading back computed cells in Excel with the stale copy closed first — balance-sheet check zero in all twelve columns; FY2025A operating loss and adjusted EBITDA both tie to the filed and reported figures.